<DOC>
	<DOCNO>NCT02348450</DOCNO>
	<brief_summary>This study aim evaluate progression-free survival ( PFS ) also survival IP EP ( head-to-head ) first line therapy extensive stage small-cell lung cancer explore reasonable first-line therapy Chinese population . An open-label , multi-center study conduct dynamic randomization approximately 1:1 ratio estimation 308 eligible participant .</brief_summary>
	<brief_title>Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin Extensive Stage Small-cell Lung Cancer</brief_title>
	<detailed_description>evaluate progression-free survival ( PFS ) also survival IP EP ( head-to-head ) first line therapy extensive stage small-cell lung cancer explore reasonable first-line therapy Chinese population . An open-label , multi-center study conduct dynamic randomization approximately 1:1 ratio estimation 308 eligible participant .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Cytologically histologically confirm extensive stage smallcell lung cancer ( remote metastasis and/or contralateral lymphnode involvement ; simple ipsilateral pleural effusion ) ; No prior radiotherapy , chemotherapy surgery ; At least one measurable lesion , CT≥20mm , spiral CT≥10mm ( diameter ) ; ECOG PS 01 ; Age 1870 ; Life expectancy &gt; three month ; In general normal function heart , liver , kidney bone marrow ; WBC C＞4.0×10 ( 9 ) /L , NEUT＞1.50×10 ( 9 ) /L , PLT＞100×10 ( 9 ) /L , Hb＞95g/L ; Liver function : TBIL &lt; 1.5 x UL normal range ; ALT AST &lt; 1.5 x UL normal range ; Kidney function : normal serum creatinine level ; Signed informed consent comply study protocol followup plan . Failed meet entry criterion pathology clinical stage ; Have receive prior chemotherapy target treatment ; Currently receive anticancer therapy ; No measurable lesion lesion assess ; Patients acute chronic medical psychiatric condition , laboratory abnormality may impact judgment investigator result study , determine investigator may include : Uncontrolled tumor metastasis central nerve system ; Uncontrolled hypertension , unstable angina , MI history , congestive heartfailure , uncontrolled arrhythmia , ischemic vascular disease within 12 month prior study treatment ; Myocardial ischemia ECG valvular heart disease ; Grade 3 peripheral neuropathy ; Active stage infection bacteria , fungi virus ; Pregnant breast feed woman ; History uncontrolled mental disease . Not able discontinue NSAIDs treatment ; Other active malignant tumor except nonmelanoma skin cancer , insitu cervical carcinoma cure early prostatic carcinoma ; Patients allergy , know may allergic drug research ; Patients poor compliance treatment followup ; Patients UGT1A16 UGT1A128 gene mutation ; With clinical symptom brain metastasis ( patient stable clinical performance need treat include trial ) ; Chest , abdominal pericardial effusion need anticancer intervention ; Accompanied Grade ≥2 diarrhea ; Participated clinical trial within one month randomization ; Investigator 's judgment exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>